EP0584251A4 - MOLECULES TARGETED TO A CYTOKINE RECEPTOR BY THE TREATMENT OF NEOPLASTIC CELL GROWTH. - Google Patents

MOLECULES TARGETED TO A CYTOKINE RECEPTOR BY THE TREATMENT OF NEOPLASTIC CELL GROWTH.

Info

Publication number
EP0584251A4
EP0584251A4 EP92912726A EP92912726A EP0584251A4 EP 0584251 A4 EP0584251 A4 EP 0584251A4 EP 92912726 A EP92912726 A EP 92912726A EP 92912726 A EP92912726 A EP 92912726A EP 0584251 A4 EP0584251 A4 EP 0584251A4
Authority
EP
European Patent Office
Prior art keywords
treatment
cell growth
cytokine receptor
neoplastic cell
molecules targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92912726A
Other languages
German (de)
French (fr)
Other versions
EP0584251A1 (en
Inventor
Cory Ann Waters
Louis R Poisson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seragen Inc
Original Assignee
Seragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seragen Inc filed Critical Seragen Inc
Publication of EP0584251A1 publication Critical patent/EP0584251A1/en
Publication of EP0584251A4 publication Critical patent/EP0584251A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP92912726A 1991-05-17 1992-05-15 MOLECULES TARGETED TO A CYTOKINE RECEPTOR BY THE TREATMENT OF NEOPLASTIC CELL GROWTH. Withdrawn EP0584251A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70193291A 1991-05-17 1991-05-17
US701932 1991-05-17

Publications (2)

Publication Number Publication Date
EP0584251A1 EP0584251A1 (en) 1994-03-02
EP0584251A4 true EP0584251A4 (en) 1995-08-02

Family

ID=24819258

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92912726A Withdrawn EP0584251A4 (en) 1991-05-17 1992-05-15 MOLECULES TARGETED TO A CYTOKINE RECEPTOR BY THE TREATMENT OF NEOPLASTIC CELL GROWTH.

Country Status (4)

Country Link
EP (1) EP0584251A4 (en)
JP (1) JPH06507900A (en)
CA (1) CA2103258A1 (en)
WO (1) WO1992020364A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0800829B2 (en) * 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin
AU5088600A (en) * 1999-06-03 2000-12-28 Bioinnovation Limited Gene therapy products
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001004A1 (en) * 1989-07-06 1991-01-24 Seragen, Inc. Hybrid molecules
WO1991002000A1 (en) * 1989-08-02 1991-02-21 Seragen, Inc. Il-2 deletion mutants
WO1991019745A1 (en) * 1990-06-13 1991-12-26 The University Hospital Chimeric toxins with improved inter-domain geometry

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US5084556A (en) * 1987-10-23 1992-01-28 Genetics Institute, Inc. Composition of M-CSF conjugated to cytotoxic agents and a method for treating cancers characterized by over-expression of the c-fms proto-oncogene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001004A1 (en) * 1989-07-06 1991-01-24 Seragen, Inc. Hybrid molecules
WO1991002000A1 (en) * 1989-08-02 1991-02-21 Seragen, Inc. Il-2 deletion mutants
WO1991019745A1 (en) * 1990-06-13 1991-12-26 The University Hospital Chimeric toxins with improved inter-domain geometry

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BACHA, PATRICIA A. ET AL: "Impact of interleukin -2- receptor -targeted cytotoxins on a unique model of murine interleukin -2- receptor -expressing malignancy", INT. J. CANCER (1991), 49(1), 96-101 CODEN: IJCNAW;ISSN: 0020-7136 *
C. F. LEMAISTRE ET AL.: "PHASE I-II EVALUATION OF AN IL-2 RECEPTOR TARGETED FUSION TOXIN DAB-486 IL-2 FOR TREATMENT OF AIDS-ASSOCIATED KAPOSI'S SARCOMA.", ISITITUTO SUP. DI SANITA. VII INTERNATIONAL CONFERENCE ON AIDS: SCIENCE CHALLENGING AIDS; FLORENCE, ITALY, 16 June 1991 (1991-06-16), pages 79 *
CHARLES F. LEMAISTRE ET AL.: "THERAPEUTIC EFFECTS OF GENETICALLY ENGINEERED TOXIN (DAB486IL-2) IN PATIENT WITH CHRONIC LYMPHOCYTIC LEUKAEMIA.", LANCET THE, vol. 337, 11 May 1991 (1991-05-11), LONDON GB, pages 1124 - 1125 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; *
NICHOLS, J. C. ET AL: "Development of IL-2-toxin ( DAB486 -IL-2) for human clinical trials in interleukin -2 receptor positive malignancies", ZENTRALBL. BAKTERIOL., SUPPL. (1990), 19(BACT. PROTEIN TOXINS), 479-87 CODEN: ZBASE2 *
See also references of WO9220364A1 *
TESUYUKI KIYOKAWA ET AL.: "PROTEIN ENGEERING OF DIPHTERIA-TOXIN-RELATED INTERLEUKIN-2 FUSION TOXINS TO INCREASE CYTOTOXIC POTENCY FOR HIGH-AFFINITY IL-2-RECEPTOR-BEARING TARGET CELLS.", PROTEIN ENGINEERING, vol. 4, no. 4, ENGLAND GB, pages 463 - 468 *

Also Published As

Publication number Publication date
WO1992020364A1 (en) 1992-11-26
CA2103258A1 (en) 1992-11-18
JPH06507900A (en) 1994-09-08
EP0584251A1 (en) 1994-03-02

Similar Documents

Publication Publication Date Title
EP0603194A4 (en) MOLECULES TARGETED TO AN EPIDERMAL GROWTH FACTOR RECEPTOR FOR USE IN THE TREATMENT OF INFLAMMATORY ARTHRITIS.
FI925358A7 (en) WATER TREATMENT PLANT
ID1033B (en) STRUCTURE OF MONTATION USING SCREWED CONCEPT SHAPES FOR PIPES
FR2621323B1 (en) INTENSIVE AND CONTROLLED PRODUCTION DEVICE FOR MICROORGANISMS BY PHOTOSYNTHESIS
DE69013614D1 (en) Limb support or splint.
EP0590090A4 (en) SELECTIVE INHIBITION OF THE PROLIFERATION OF LEUCEMIC CELLS BY ANTI-CODING OLIGONUCLEOTIDES -i (BCR-ABL).
IT1078665B (en) WASTEWATER TREATMENT PROCESS AND PLANT
DE69229878D1 (en) WASTEWATER PLANT
EP0668774A4 (en) INTERLEUKIN RECEPTOR TARGETED MOLECULES FOR THE TREATMENT OF INFLAMMATORY ARTHRITIS.
DE68914635D1 (en) ADJUSTABLE SUPPORT.
MX9203919A (en) PROCEDURE TO PURIFY ORGANOPOLISILOXANES.
EP0584251A4 (en) MOLECULES TARGETED TO A CYTOKINE RECEPTOR BY THE TREATMENT OF NEOPLASTIC CELL GROWTH.
ES275528Y (en) ADJUSTABLE SUPPORT
DE3870197D1 (en) ADJUSTABLE ADJUSTMENT.
IT8420610A0 (en) PROCEDURE TO IMPROVE THE GROWTH OF PLANTS THROUGH INTERMITTENT LIGHTING.
MX9206689A (en) METHOD TO PURIFY POLYACRYLONITRILE
ATA78091A (en) WASTEWATER TREATMENT PLANT
ATA233886A (en) WASTEWATER TREATMENT PLANT
MX9205366A (en) METHOD TO NEUTRALIZE THE ADVERSE EFFECTS OF CYTOKINE IL-1.
IT8722145A0 (en) ADJUSTABLE BLOCK GROUP WITH CARCANIC JOINT TO SUPPORT STRUCTURES ON CYLINDRICAL ELEMENTS.
IT8223792A0 (en) DEVICE FOR BIOLOGICALLY ACTIVATED WATER PURIFICATION.
FR2313323A1 (en) BIOLOGICAL WASTEWATER TREATMENT PLANT
ITRM910407A1 (en) PROCEDURE FOR THE PURIFICATION TREATMENT OF MUNICIPAL WASTEWATER, AND PLANT USING THE PROCEDURE
ES1020188Y (en) DEVICE TO HELP SEXUAL ACTIVITY.
IT8709500A0 (en) SEWAGE PURIFICATION PLANT

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950615

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19970402

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19971014